ERBB2 and neoplasm: Although the introduction of anti‐HER2 therapies has dramatically improved the cure rate and survival expectancy of patients with early stage and advanced‐stage HER2‐positive BC, respectively, tumor sensitivity to anti‐HER2 treatments is highly heterogeneous (Loibl & Gianni, 2017).